Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

Patients will first be screened using the G8 screening tool. If the resulting score is altered (G8 <= 14), patients will be included in the main study and randomized according to 2 modalities: Arm A / Usual care (treatment according to on-going regimens in oncology) or Arm B /Case management (assessment of the patient by the nurse and the geriatrician with interventions as prescribed by the geriatrician). The intervention will be considered effective if, at one year, compared to usual care there is a significant clinical improvement in overall survival (OS) without a significant deterioration or/and clinical improvement of at least one of the targeted quality of life (QoL) scores, without significant clinical deterioration in at least one of the targeted QoL scores and without significant difference in OS in favor of usual care.

If the resulting score is normal (G8 > 14), patients will be treated according to their physician-in-charge opinion. A minimal set of data will be collected (age, sex, tumor type, disease stage, performance status (PS), creatinine clearance, albumin and C-Reactive Protein (CRP) levels mainly) to allow for the characterization of the population in order to compare our results to those of other published series.

Inclusion criteria

• Patient older 70 years and older
• Performance status 0 to 3 (WHO)
• G8 and QLQ-C30 questionnaires 'score are available
• No previous geriatric evaluation during cancer treatment
• Locally advanced or metastatic disease :

• 1st line medical treatment :

• Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
• Colon and rectum : metastatic (unresectable metastasis),
• Prostate cancer : metastatic and refractory to hormonal castration,
• Bladder cancer : locally advanced or metastatic,
• Ovarian cancer : advanced stage (IIb to IV),
• Lung cancer : metastatic non-small cell,
• Lymphomas (indolent and aggressive)
• Or 2nd line medical treatment :

• Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
• Colon and rectum : metastatic (unresectable metastasis),
• Prostate cancer : metastatic and refractory to hormonal castration,
• Ovarian cancer : advanced stage (IIb to IV),
• Lymphomas (indolent and aggressive)
• Life expectancy over 6 months
• Signed informed consent
• Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).

Exclusion criteria

• Patient who already received 2 medical treatment lines
• Exclusive 1st or 2nd treatment lines of :

• Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed),
• Surgery,
• Radiotherapy,
• "Best supportive care" treatment
• Patient unable to understand quality of life questionnaire
• Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
• Patient placed under guardianship
• Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE
• Previous enrolment in the present study